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ABSTRACT 
Objective: The aim of this study was to investigate in vitro and in vivo behavior of the prepared ethosomal formulations of green tea extract, which 
in turn would result in enhancing their therapeutic efficacy as antioxidants and thermogenic agents in obese mice. 
Methods: Fat Wistar rats were acclimated for at least 7 d in environmentally controlled cages, then they were divided into five groups: 1st received 
only distilled water, 2nd received an oral dose of green tea extract, in 3rd group green tea extract loaded gel base was applied on the previously 
shaven dorsal side of rats and in the other 2 groups selected green tea extract loaded Ethosomal gel base were applied on the previously shaven 
dorsal side of rats. Total antioxidant capacity by ferric reducing ability of plasma (FRAP) method, catalase enzyme activity, malondialdehyde (MDA) 
and thiobarbituric acid reactive substance (TBARs) levels, and real-time qPCR of UCP2 and 3 were then determined. 
Results: Formulation of green tea extract as ethosomal preparations exhibited a controlled release rate due to the reservoir action of ethosomes. 
The levels of TBARs and MDA were lower in groups supplemented with green tea extracts compared to control group and in groups (3-5) received it 
transdermal (P<0.0001 in all 3 groups) was lower than group received it orally with P = 0.0081. The messenger RNA levels of UCPs 2 and 3 in BAT 
were increased in those 3 groups.  
Conclusion: The results support the efficiency of ethosomal gel in penetrating the lipid rich biological membrane. The in vivo study confirms the 
antioxidant and thermogenic behavior of transdermal applied green tea extract.  
Keywords: Bioavailability, Lecithin, Green tea extract, Transdermal, Ethosome, Uncoupling proteins (UCPs) and Real-Time Polymerase Chain 
Reaction (RT-PCR) 
© 2020 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/) 
DOI: http://dx.doi.org/10.22159/ijpps.2020v12i11.39276. Journal homepage: https://innovareacademics.in/journals/index.php/ijpps.  
 
INTRODUCTION 
Thousands of years ago (started in prehistoric times), natural products, 
such as plants, microorganisms, animals, and marine organisms, have 
been used to relieve and treat many diseases [1]. The replacements of 
normally used drugs with natural products, must of course, have 
presented a tremendous challenge to humans all overages. Green tea 
(Camellia sinensis) (fam. Theaceae) has been confirmed as safe agent 
with many benefits as one of the extremely important natural products 
[2]. Epigallocatechin gallate (EGCG) is the main effective component in 
green tea leaves extract and is responsible for many health beneficial 
effects. EGCG has a high antioxidant activity that can provide protection 
to the body from the risk of cardiovascular diseases, diabetes mellitus, 
cancer, and neurodegenerative disorders, obesity and exhibits anti-
inflammatory effects [3, 4]. 
In alkaline media (like small intestine) EGCG is found to be of low 
absorption rate as less as 5% of EGCG reach the systemic circulation 
[5]. The majority amount of EGCG thereafter will be degraded by 
intestinal micro flora in the colon [6].  
To overcome these problems, an alternative drug administration route 
such as transdermal drug delivery system is used, which can deliver 
drugs through the skin up to the systemic circulation [7]. This route is 
characterized by avoidance of gastrointestinal degradation; first pass 
effect, and drug fluctuations in the blood [8]. To provide optimal 
antioxidant and thermogenic effects, then the bioactive component of 
green tea (i.e., EGCG) should penetrate the skin. It is an issue, because 
of high polarity value of the hydrophilic molecule (log p=0.48), and a 
considerable molecular weight of (458.37 da) [9, 10]. 
To overcome this, formulation of green tea leaves extracts into a 
carrier-based lipid (i.e., ethosomes) is done to enhance its 
penetration through skin. Ethosomal carriers are systems of soft 
vesicles. They are mainly composed of (ethanol) and phospholipid 
(lecithin) at relatively high concentrations, with water as a non-
solvent. Interacting with lipid molecules (found in polar head group 
region ( , ethanol reduces the phase transition temperature (Tm) of the 
stratum corneum lipids, leading to an increase in fluidity. Moreover, 
this reaction results in an increase in membrane permeability. In 
addition, there is an interaction between ethosome itself and the 
stratum corneum barrier. Ethanol also gives the vesicles flexibility and 
softness [11]. Ethosomes can deliver hydrophilic and hydrophobic 
probes to a depth of 170 µm with greater intensity than the control 
systems [12]. However, high cost of phospholipids and their variable 
purity are sproblems of ethosomes. 
Brown adipose tissue (BAT) is an important site for thermogenesis. 
Due to its high metabolic capability to maintain body temperature in 
cold conditions or to waste food energy, it is currently considered a 
novel therapeutic option for obesity management. BAT 
thermogenesis is mainly dependent on the action of uncoupling 
proteins (UCPs), which causes conversion of the driving force of 
adenosine triphosphate (ATP) synthesis into heat via uncoupling the 
process of oxidative phosphorylation in the mitochondria [13].  
The aim of this study was to optimize conditions for encapsulating 
green tea extract and examine the in vitro and in vivo efficacy of 
ethosomes on the rat skin when applied as topical formulation. 
Furthermore, the results should contribute to a better understanding 
of the antioxidant and thermogenic effects of green tea extract (EGCG) 
with advancing its bioavailability. In addition, messenger RNA (mRNA) 
expression of Uncoupler proteins types II and III genes related to 
thermogenesis and antioxidant effects were evaluated. 
MATERIALS AND METHODS 
Materials  
We purchased Green tea leaves extract (Camellia sinensis) from 
(Andy Biotech Co. Ltd., China with standard potency 98.4 %.). 
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Kindly, (Futures manufacture, Egypt) provided us with lectithin and 
(Sekem development foundation, Egypt) provided us with EGCG 
standard. A cellophane membrane (Molecular weight cut of 12000-
14000) was purchased from United States (USA). 
Methods 
HPLC determination of EGCG in green tea extract  
EGCG percentage was accurately measured spectrophotometrically 
by High performance liquid chromatography (HPLC) in green tea 
extract against EGCG standard [14] at 278 wavelength [15]. 
Preparation of ethosomes encapsulating green tea extract 
Preparation of Ethosomes 
Ethosomes were prepared by slight modification of cold method [11]. 
Initially Lecithin was taken and dissolved in ethanol by use of magnetic 
stirrer in completely closed flask at 30 °C. To this solution, 50 mg of the 
green tea extract dissolved in hot distilled water (30 °C) was added as 
fine stream by the use of syringe very slowly. The volume was made up 
using distilled water (30 °C), thereafter whole system was whiskered for 
15 min at 900 rpm. Further, it was sonicated for 5-15 min. Finally, the 
formulations were stored under refrigeration. We prepared 12 batches 
of ethosomes using varying concentrations of lecithin (1-3%) and 
ethanol (10-40%). (Table 1) The most two stabilized ethosomes with 
high entrapment efficiency and lower Poly Dispersity Index were selected 
for the preparation of two individual vesicle incorporated gel 
formulations and further selected in vivo study. 
Characterization of ethosomes 
Morphology and structure of ethosomes 
For visualization of sample by Scanning Electron Microscopy (SEM), 
one drop of ethosomal system was mounted on a stub covered with 
a clean glass. The drop was spread out on the glass homogenously. 
The ethosomal dispersion was spread on the glass slide using a glass 
rod. Formation of multilamellar vesicles was confirmed by 
examining the ethosomal suspension under an optical microscope 
with the magnification power of 100X (Olympus). Olympus camera 
was used for Photography. 
 
Table 1: Composition of ethosomal vesicles 
Formula code Lecithin % Ethanol: water Green tea extract (mg) 
T1 1 10:90 50 
T2 1 20:80 50 
T3 1 30:70 50 
T4 1 40:60 50 
T5 2 10:90 50 
T6 2 20:80 50 
T7 2 30:70 50 
T8 2 40:60 50 
T9 3 10:90 50 
T10 3 20:80 50 
T11 3 30:70 50 
T12 3 40:60 50 
12 batches of ethosomes were prepared using varying concentrations of lecithin (1-3%) and ethanol (10-40%). 
 
Determination of entrapment efficiency (EE %) 
The entrapment efficiencies of ethosomal preparations were 
determined by HPLC after dispersion in phosphate buffer. The 
ethosomal dispersion obtained was centrifuged at 10000 rpm. Then, 
supernatant was assayed for free drug [16]. 
Particle size and polydispersity index 
Particle size and index polydispersity were measured using a 
particle size analyzer. The measurements were repeated. The 
polydispersity index was conducted to evaluate the particle 
distribution of ethosomes [17-19]. 
In vitro drug release studies 
The in vitro permeation behaviour of green tea extract from 
ethosomal formulations was investigated using diffusion cell model. 
The diffusion cell was consisted of a cellophane membrane filled 
with ethosomal preparation, which was placed in a receptor 
compartment containing phosphate buffer agitated at 100 rpm at 
37±0.5 °C. An aliquot of 2 ml sample was withdrawn at 
predetermined time intervals over 24 h and replaced immediately 
with an equal volume of fresh diffusion medium. The samples were 
filtered and analyzed using HPLC [20-23]. 
In vivo study 
Grouping and dose administration 
We used Fat Wistar rats (250±50 g) for our current study (supplied 
by the animal house in the faculty of medicine, Zagazig University). 
Ethical clearance for our study was obtained from the Institutional 
Review Board (IRB/08/2019), Zagazig University, Egypt. Rats were 
adapted for 7 d in environmentally controlled (23 °C±1 °C and 
equally half day dark/light cycle) cages, with free consumption of 
standard food and water and fasted overnight before the 
experiments. We divided them into 5 groups (ten rats per group): 
 1st GROUP (control): were given distilled water only 
 2nd GROUP (standard): were given (by oral feeding needles) oral 
dose of green tea extract. 
 3rd GROUP: we applied loaded gel base with green tea extract on 
the shaven dorsal side of rats. 
 4th and 5th GROUPS: we applied dose equivalent to 100 mg/kg 
body weight of selected green tea extract loaded Ethosomal gel base 
(T10 and T12) on shaven dorsal side of rats [24].  
Animals were sacrificed after daily dosing for 7 d. A central 
longitudinal incision was made in the abdominal wall and blood 
samples were collected by cardiac puncture. Blood samples were 
centrifuged at 1500 × g for 20 min at 4 °C and the plasma was 
separated and stored at −20 °C until analyzed. The BAT was harvested, 
frozen immediately in liquid nitrogen, and stored at −70 °C. Liver from 
each animal was excised and its homogenate was prepared and 
centrifuged for 5 min at 4 °C. The supernatant obtained was further 
used for antioxidant assay [25]. Different specimens of the liver, 
kidney and brain were embedded in paraffin blocks, stained and 
observed for any changes under light microscope [26]. 
Assay of total antioxidant capacity (TAC) 
We measured total antioxidant capacity by ferric reducing ability of 
plasma (FRAP) method, which is based on the capability of plasma to 
reduce Fe3+to Fe2+in the presence of TPTZ (2,4,6-tripyridyl-s-trlazine) 
[27]. 
Determination of catalase activity  
The activity of catalase (CAT) was assayed following (Pari and 
Latha) method [28].  
Estimation of lipid peroxidation 
We determined levels of malondialdehyde (MDA) and thiobarbituric 
acid reactive substance (TBARs) production by (Draper and Hadley) 
method [29].  
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Real-time qPCR 
Total RNA was extracted from BAT using TRIzol Reagent 
(Invitrogen, Carlsbad, CA, USA). The complementary DNA (cDNA) 
was prepared from 1μg RNA using Maxime RT PreMix (iNtRON). 
After cDNA synthesis, 2μl of first-strand cDNA was used for real 
time PCR (RT-PCR) in 20μl reactions containing 10 ul of 
Universal SYBR Green PCRMaster Mix (Qiagen, Chatsworth, CA, 
USA), 1ul of each primer and 4ul PCR grade water in thermal 
cycler (DTlite 4 DNA-TECHNOLOGY, Russia). The sequences of 
the sense and antisense primers used for amplification are 
shown in table 2. 
 
Table 2: Primers used for the real-time quantitative polymerase chain reaction 
Gene Sense primer (5’-3’) Antisense primer (5’-3’) 
UCP-2 GACCTATGACCTCATCAAGG ATAGGTGACGAACATCACCACG 
UCP-3 ATGGACGCCTACAGAACCAT TACGAACATCACCACGTTCC 
β-actin AGAGCTACGAGCTGCCTGAC AGCACTGTGTTGGCGTACAG 
The sequences of the sense and antisense primers for UCP-2, UCP-3 and β-actin 
 
The ΔΔCt method was used for measuring relative quantification 
[30]. We determined the ΔΔCt value for each sample by calculation 
of the difference between the target gene Ct value and the β-actin Ct 
value as a reference gene. The normalized level of the target gene 
expression in each sample was calculated using the formula 2−ΔΔCt. 
Values were expressed as fold change relative to the control group. 
Statistical analysis 
All data are presented as mean±SD (standard deviation). We 
conducted Statistical analysis using (SPSS) (version 17; IBM 
Corporation, Armonk, NY, USA). P<0.05 was considered as an 
indication of a statistically significant difference. 
RESULTS  
HPLC determination of EGCG in green tea extract 
Amount of EGCG presented in green tea extract was measured at 278 
wavelengths; this wavelength was advised by Huo et al. [31]. By 
optimizing HPLC conditions, the concentration of EGCG in the working 
green tea extract sample solution was determined (54.24 %) (fig. 1). To 
ensure the presence of suitable amount of EGCG within the extract with 
further dilutions, we constructed a calibration curve (fig. 2). 
 
 
Fig. 1: HPLC profile of Green tea extracts (a) chromatogram of EGCG standard and (b) chromatogram of green tea extract, by optimizing 
HPLC conditions, the concentration of EGCG in the working green tea extract sample solution was determined (54.24 %) 
 
 
Fig. 2: Calibration curve of EGCG in green tea extract, to ensure the presence of a suitable amount of EGCG within the extract with further 
dilutions, we constructed a calibration curve 
 
Preparation of ethosomes encapsulating green tea extract 
Irrespective of whether transdermal absorption has a local effect or 
systemic action, the drug should pass through the stratum corneum. 
Because of the barrier effect of stratum corneum, the majority of 
drugs cannot give their required therapeutic effect when applied 
topically. Recently, ethosomes are widely used for transdermal 
delivery because they not only easily pass through the skin but also 
increase the accumulation of drug in the skin. Dayan, N., and 
Touitou, E., concluded that when compared with normal 
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liposomethe, steady-state transdermal rate of trihexyphenidyl 
hydrochloride ethosomes composed of phospholipid, ethanol, and 
water increased by 87 fold [32]. In our current study, to enhance the 
transdermal penetration of green tea extract, ethosomal 
formulations were prepared and they were further incorporated 
into gels. 
Ethosomal dispersal was enhanced with increasing amounts of 
lecithin concentration (1, 2, and 3%) and ethanol (10, 20, 30, and 
40%). In all these dispersions, ethanol concentration with different 
percentages induced white milky suspensions without any 
significant differences under the macroscopic view. As one of the 
broad parameters for the evaluation of prepared ethosomes quality 
according to the basis of their particle size distribution, Poly 
Dispersity Index (PDI) was including with a value of 0-1 as 
reference. The preparations presenting PDI in this range were then 
evaluated based on their drug entrapment efficiency and vesicular 
size (table 3). PDI index range was (0.043-0.282). 
 
Table 3: Entrapment efficiency, vesicle size and polydispersity index of the various ethosomal preparations 
F Drug content % mean±SD EE % mean±SD Vesicle size (nm) mean±SD Polydispersity index (PDI) mean±SD 
T1 63.77±2.49 60.93±2.34 184.22±2.33 0.067±0.003 
T2 71.08±1.37 64.51±0.98 134.82±0.72 0.049±0.001 
T3 73.18±0.94 69.21±1.33 112.65±1.56 0.038±0.002 
T4 76.4±0.81 71.39±1.52 100.23±1.3 0.043±0.003 
T5 79.29±2.01 73.94±2.27 222.32±0.98 0.210±0.019 
T6 83.4±0.11 78.82±0.42 200.81±1.44 0.088±0.008 
T7 85.46±1.61 79.9±2.3 169.2±2.74 0.067±0.005 
T8 87.14±0.67  81.59±1.68 145.72±1.07 0.058±0.002 
T9 89.78±0.3 85.63±1.03 314.04±1.32 0.279±0.013 
T10 90.9±1.22 87.91±2.69 309.68±0.78 0.121±0.011 
T11 91.93±0.52 88.5±1.94 299.5±0.99 0.282±0.024 
T12 93.32±1.54* 90.11±0.81 287.06±1.01 0.117±0.029 
Values are presented as mean±SD, PDI index range was (0.043-0.282), formulation T12* (93.32 %) showed maximized drug content with maximal 
ethanol content and increased lecithin concentration. 
 
Shape and size of the vesicle are critical factors in transdermal drug 
delivery system therapeutic performance. In our current study, 
phase-contrast microscopy showed the surface morphology of 
ethosomes (fig. 3). 
 
 
Fig. 3: Microscopical image of ethosomal dispersion 
 
Phase contrast microscopy showed the surface morphology of 
ethosomes 
Minimum and maximum vesicle sizes were observed to be 100.23 
nm and 314.04 nm, respectively, depending on the concentration 
of ethanol and lecithin. The vesicles size was found to increase 
with lecithin concentration increase from (1–3%), while it was 
inversely related to concentration of alcohol (higher alcohol 
concentrations accompanied with lower vesicle size). This 
observation agreed with the Elsayed et al. findings [33] that higher 
concentration of ethanol allows a surface negative net charge to 
the vesicular systems by surface characteristics manipulation, this 
leads to a decrease in vesicles size. When we kept lecithin amount 
at 1% while increased ethanol concentration from 10% to 40%, a 
decrease in vesicles size from (184.22 to 100.23 nm) was 
observed. Likewise, vesicles size decreased from (222.32 to 
145.72) nm and from (314.04 to 287.06 nm) with lecithin 
concentration 2% and 3%, respectively and with the same 
increase in ethanol concentration (table 3). 
Entrapment efficiency is used as a quality parameter, which has a 
direct effect on the delivery potential of the vesicular systems and to 
be determined in the formulated ethosomal vesicles, the drug 
content in each preparation was to be determined first. Drug content 
ranged from 63.77±2.49 % to 93.32±1.54 % that shows good 
capacity of formulation to hold the drug. Formulation T12 (93.32 %) 
showed maximized drug content with maximal ethanol content and 
increased lecithin concentration. 
Ethanol and lecithin amounts and concentrations had a positive 
effect on the entrapment of the herbal extract inside lipid vesicles. 
Entrapment efficiency was showed to be 87.91 % with 20% ethanol 
and 3% lecithin formulation (T10), while increased to 88.5% and 
90.11% with alcohol concentration increase to 30% and 40%, 
respectively, and lecithin concentration kept unchanged at 3% (table 
3). This increase is probably due to accelerated green tea extract 
solubility in water present in the ethosomal core. Concentration of 
ethanol in the ethosome system should be maintained below 45%. In 
our study, when concentration exceeded 40%, drug leakage from the 
lipid bilayer started, leading to decreased entrapment percentage. 
Our data agreed with Paolino et al. findings and conclusion [34]. 
In vitro drug release studies through cellophane membrane  
The initial drug release should be fast enough to guarantee the 
maintenance of therapeutic drug levels in vivo in a timely way [35, 
36].  
As shown in (fig. 4), the release of all prepared ethosomal 
formulations after 24 h exceeded 50 %. Green tea extract formulated 
as ethosomal preparations showed a controlled release rate due to 
ethosomes’ reservoir action. The impulse effect over the first six 
hours was clearly observed, with a following step of slower release, 
this finding might be linked with the feature of the bilayer or 
ethosomal structure [37-39]. The release rate then increased 
gradually with ethanol concentration increasing from 20 to 40 %. 
Moreover, a higher released amount was observed with increasing 
lecithin concentration which might be related to increased drug 
solubility [40] as well as increased lipid bilayer fluidity, which leads 
to drug release improvement [41, 42]. 
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Fig. 4: Release profiles of all the prepared ethosomes (each value was an average of three measurements±SD 
 
The release of all prepared ethosomal formulations after 24 h 
exceeded 50 %. Green tea extract formulated as ethosomal 
preparations showed a controlled release rate due to ethosomes’ 
reservoir action. 
Therefore, both T10 and T12 formulations were selected as the 
optimized green tea extract ethosomal formulations, that showed 
higher EE %, lower polydispersity index, as well as optimum 
release, consequently increasing penetrability and bioavailability 
[43]. 
In vivo study 
Green tea extracts supplementation effect on ferric reducing ability 
of plasma (table 4), demonstrates the variation between the 1st 
group (control) and the others. FRAP level was noticed to be 
increased in groups supplemented with green tea extracts compared 
to control. It was higher in all transdermal receiving (3rd, 4th, and 5th) 
groups (P<0.0001 in all 3 groups and 95% CI 0.7915 to 1.1485 in 4th 
group) than the 2nd group (orally receiving) with P = 0.0035 and 
95% CI 0.1758 to 0.7642.  
 
Table 4: Ferric reducing ability of plasma and changes in the activity of catalase and in TBARs and MDA production in different study 
groups 






Control group 1.13±0.19 2.4±0.29 5.04±0.78 3.5±0.21 
Standard group 1.65±0.40 4.075±0.56 4.2±0.34 2.4±0.09 
Group III 1.9±0.15 5.125±0.26 2.6±1.1 2.18±0.06 
Group IV 2.1±0.19* 5.075±0.23 ** 3.01±0.34* 2.21±0.043 
Group V 2.1±0.29* 5.425±0.46 3.2±1.01* 2.14±0.05 
Values are presented as mean±SD*: statistically significant compared to corresponding value of other groups (P<0.05)  
 
Additionally, Green tea extracts supplementation effect on the activity of 
catalase enzyme (table 4), demonstrates the variation between the 1st 
group (control) and the others. CAT enzyme activity levels were noticed 
to be influenced in groups supplemented with green tea extracts 
compared to control. It was better in all transdermal receiving (3rd, 4th, 
and 5th) groups (P<0.0001 in all 3 groups and 95% CI 2.6387 to 3.3613 
in group 5) than the 2nd group (orally receiving) with P<0.0001 and 95% 
CI 1.5810 to 2.4190. In the current study, we confirmed that the activity 
of catalase enzyme is unregulated by catechins.  
Also, Green tea extracts supplementation effect on production of 
thiobarbituric acid reactive substance (TBARs) and malondialdehyde 
(MDA) (table 4), demonstrates the variation between the 1st group 
(control) and the others. TBARs and MDA levels were noticed to be 
lower in groups supplemented with green tea extracts compared to 
control group. Additionally, it was lower in all transdermal receiving 
(3rd, 4th, and 5th) groups (P<0.0001 in all 3 groups and 95% CI-
3.2959 to-1.5041 in-group 3) than the 2nd group (orally receiving) 
with P = 0.0081 and 95% CI-1.3653 to-0.2347.  
On observation of plasma lipid profile changes (table 5), there was a 
decrease in cholesterol concentration by 12% in the 2nd group 
supplemented with green tea extracts orally compared to the 1st 
control group, and by 20%, 10% and 22% in transdermal receiving 
(3rd, 4th, and 5th) respectively. Regarding HDL level, no effect was 
observed in 2nd group (orally receiving) compared to control group. 
However, it increased in all transdermal receiving (3rd, 4th, and 5th) 
groups in relation to control group. The Triglycerides, LDL and VLDL 
levels were decreased in all green tea extract supplemented groups 
compared to control group. 
  
Table 5: Changes in lipid profile in different study groups 










Control group 110±5 58±3 159±3 60±0.2 10±3 
Standard group 91±3 58±3 126±3 50±0.9 12±5 
Group III 89±2 64±3 102±5 43±0.9 13±3.2 
Group IV 90±2.5 60±2 112±3 35±1 11±3 
Group V 86±3 62±1.6 118±2.5 33±1.6 9±4 
Values are presented as mean±SD: HDL levels were increased in all transdermal-receiving (3rd, 4th, and 5th) groups in relation to control group. The 
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Triglycerides, LDL and VLDL levels were decreased in all green tea extract supplemented groups compared to control group.  
 
Fig. 5: Different histological specimens of experimental rats 
 
Histopathological observation of tissues of various organs (brain, 
liver, and kidney) after administration of green tea extract (orally 
and transdermal) (fig. 5) showed no changes in the organs’ tissues 
and cells of rats’specimens. Confirming that short time periods and 
such doses of oral and/or transdermal administration of green tea 
extract formulations doesn’t cause any toxicity to brain, liver, nor 
kidney of the tested rats. 
Fig. different histological specimens of experimental rats (H and E, 
×400) (a) liver, (b) kidney and (c) brain, show normal tissues with 
non-remarkable changes with control specimens. 
To determine the relationship between EGCG supplementation and 
anti-oxidation or thermogenesis, the mRNA levels of UCP2 and UCP3 
were measured in BAT. Transdermal administration of green tea 
extract formulations significantly increased the mRNA levels of 
UCP2 and UCP3 in groups 3-5 compared with those in the control 
group. Values for the 4th group are expressed as the fold change 
compared with those for the control group (mean±SD, n = 10). 
p<0.001 vs. control group. 
Aster Spathulifolius extract (when administered orally) causes 
increase in the mRNA synthesis of genes like CPT1, UCP2, and UCP3 
in the muscle of induced obese rats, which are involved in 
thermogenesis. We found that the expression of UCP2 and UCP3 in 
BAT were up-regulated significantly upon transdermal 
administration of green tea extract formulations (fig. 6, 7). 
 
 
Fig. 6: Relative messenger RNA (mRNA) levels of UCP-2 gene, relative messenger RNA (mRNA) levels of UCP-2 gene in brown adipose 
tissue of rat in Epigallocatechin-3-gallate (EGCG) groups in relation to control groups 
 
 
Fig. 7: Relative messenger RNA (mRNA) levels of UCP-3 gene, relative messenger RNA (mRNA) levels of UCP-3 gene in brown adipose 
tissue of rat in epigallocatechin-3-gallate (EGCG) groups in relation to control groups 
 
DISCUSSION In the present study, we found that FRAP was higher in all 
transdermal receiving (3rd, 4th, and 5th) groups (P<0.0001 in all 3 
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groups and 95% CI 0.7915 to 1.1485 in 4th group) than the 2nd group 
(orally receiving) with P = 0.0035 and 95% CI 0.1758 to 0.7642. 
Forester and lambert [44] and Chacko et al. [45] are in line with our 
findings. 
CAT enzyme activity levels were noticed to be influenced in groups 
supplemented with green tea extracts compared to control. It was 
better in all transdermal receiving (3rd, 4th, and 5th) groups 
(P<0.0001 in all 3 groups and 95% CI 2.6387 to 3.3613 in group 5) 
than the 2nd group (orally receiving) with P<0.0001 and 95% CI 
1.5810 to 2.4190. In the current study, we confirmed that the 
activity of the catalase enzyme is unregulated by catechins. Our 
results agreed with Li et al. [46] and Nelson et al. [47], However, 
opposed Pal et al. [48] and Chance et al. [49] findings, probably due 
to green tea extract use on induced injured animals.  
Also, TBARs and MDA levels were noticed to be lower in groups 
supplemented with green tea extracts compared to control group. 
Additionally, it was lower in all transdermal receiving (3rd, 4th, and 5th) 
groups (P<0.0001 in all 3 groups and 95% CI-3.2959 to-1.5041 in-
group 3) than the 2nd group (orally receiving) with P = 0.0081 and 
95% CI-1.3653 to-0.2347. Our findings are in line with Mohamadin et 
al., Awoniyi et al., Messarah et al., and Prabakar et al. [50-53] results. 
On observation of plasma lipid profile changes, there was a decrease 
in cholesterol concentration by 12% in the 2nd group supplemented 
with green tea extracts orally compared to the 1st control group, and 
by 20%, 10% and 22% in transdermal receiving (3rd, 4th, and 5th) 
respectively. Regarding HDL level, no effect was observed in 2nd 
group (orally receiving) compared to control group.  
However, increased in all transdermal-receiving (3rd, 4th, and 5th) 
groups in relation to control group. The Triglycerides, LDL and VLDL 
levels were decreased in all green tea extract supplemented groups 
compared to control group. Our results are consistent with the 
results of Basu et al., Bornhoeft et al., Cunha et al., and Hassan et al. 
[54-57]. However, no effect of green tea supplementation on plasma 
lipid profile was the conclusion of Princen et al., Erba et al. and 
Fukino et al. [58-60], which may be dose dependent effect.  
Dulloo et al. [61] found an increase in the 24h energy expenditure by 
supplementation of green tea extract in humans. Subsequently, they 
reported an enhancement in the oxygen uptake rate for BAT by 
giving an ethanol extract of green tea, indicating the occurrence of 
BAT thermogenesis [62]. Green tea extract increases BAT 
thermogenesis via β-adrenoreceptor stimulation [63]. Green tea 
EGCG (via stimulating UCP2 expression in WAT) was observed to 
decrease diet-induced obesity [64]. Aster Spathulifolius extract 
(when administered orally) causes increase in the mRNA synthesis 
of genes like CPT1, UCP2, and UCP3 in the muscle of induced obese 
rats, which are involved in thermogenesis [65]. We found that 
expression of UCP2 and UCP3 in BAT were up regulated significantly 
upon transdermal administration of green tea extract formulations.  
CONCLUSION 
Based on observations of present study, it can be concluded that a 
combination of 40% ethanol, 3% lecithin and 75% green tea extract 
(50 mg) can be used for the preparation of ethosomes with good 
entrapment efficiency. The in vitro release efficiency of ethosomal 
gel was found up to 92.49%, which support the potential of these 
carriers in penetrating the lipid rich biological membrane. The in 
vivo study confirms the antioxidant behavior of transdermal applied 
green tea extract. The findings suggest that EGCG may play 
important roles in regulating BAT thermogenesis and antioxidant 
effects for improving obesity. The present study revealed ethosomal 
gel as an efficient carrier for herbal extract. 
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